Professor Daniel M Berney
Honorary Professor of Genito-urinary Pathology; Consultant Pathologist
My focus is on the pathology and natural history of prostate, testicular and penile cancer working to translate basic research into practical treatments for patients with novel tests and bespoke predictive treatments.
Dr Alastair Lamb
Senior Clinical Lecturer, Barts Cancer Institute Visiting Associate Professor, Oxford University Honorary Consultant Urological Surgeon, Guy's and St Thomas' NHS Foundation Trust
Our lab focusses on Spatial Prostate Assessment and the Circulating Environment (aka the SPACE Group). We use cutting edge spatial molecular techniques to unpack clonal dynamics in the development of localised prostate cancer. Alongside this we seek to identify scalable “windows” into clonal lethality using machine learning approaches applied to histology and MRI images as well as ‘liquid biopsy’ of circulating tumour cells (CTCs). Our aim is to transform decision-making in clinical management of prostate cancer so that the right men get the right treatment at the right time.
Professor Yong-Jie Lu
Professor of Molecular Oncology
We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
Professor Thomas Powles
Professor of Genitourinary Oncology; Director, Barts Cancer Centre at St. Bartholomew's Hospital; Lead for Solid Tumour Research
My main research interests are in genital and urinary cancers, leading a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies.
Professor Prabhakar Rajan
Professor Urology and Robotic Surgery
My laboratory research explores alternative pre-mRNA splicing in prostate cancer (PCa) biology, and liquid biopsy-derived molecular biomarkers of treatment outcomes.
Dr Max Beesley
My research focuses on improving our understanding of why only certain prostate cancer clones within a patient (intratumoural) undergo metastasis. I will apply next-generation spatial transcriptomics to investigate clonal evolution, identify key driver mutations and better understand clonal interaction with the stromal tumour microenvironment (TME).
Dr Helen Ross-Adams
The aim of my work is to develop clinically-relevant biomarkers that could aid in earlier disease detection, predict treatment response, and inform clinical management of patients.